Inflammatory Breast Cancer
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Inflammatory Breast Cancer

View Main Condition: Breast Cancer

What is the definition of Inflammatory Breast Cancer?
Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin of the breast. This type of breast cancer is called 'inflammatory' because the breast often looks swollen and red, or 'inflamed.' The skin may also look dimpled like the skin of an orange. IBC can be difficult to diagnose because there is no lump to feel or detect on a mammogram. Like other types of breast cancer, IBC can occur in men, but usually at an older age than in women.
What are the alternative names for Inflammatory Breast Cancer?
  • Inflammatory breast cancer
  • Breast cancer, inflammatory
Who are the top Inflammatory Breast Cancer Local Doctors?
Elite in Inflammatory Breast Cancer
Surgical Oncology | General Surgery
Elite in Inflammatory Breast Cancer
Surgical Oncology | General Surgery
Referral may be required

Brigham And Women's Hospital, Division Of Breast Surgery

75 Francis Street, 
Boston, MA 
Languages Spoken:
English

Dr. Nakhlis received her medical degree from Rush Medical College in Chicago in 1996. She subsequently completed her residency in general surgery and her breast surgery fellowship at Northwestern University in Chicago. She is an attending physician in the Brigham and Women's Hospital and Brigham and Women’s Faulkner Hospital in Boston and an assistant professor of surgery at Harvard Medical School. Her clinical research interests are focused on lobular neoplasia and other premalignant and proliferative breast lesions, and inflammatory breast cancer. Dr. Nakhlis is rated as an Elite provider by MediFind in the treatment of Inflammatory Breast Cancer. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Intraductal Papilloma, Mastectomy, and Lymphadenectomy. Dr. Nakhlis is board certified in Surgery, General.

Elite in Inflammatory Breast Cancer
Elite in Inflammatory Breast Cancer
Referral may be required

Dana-Farber Cancer Institute, Breast Oncology Program

450 Brookline Avenue, Susan F. Smith Center For Women's Cancers, 
Boston, MA 
Languages Spoken:
English
Offers Telehealth

Dr. Lynce received her medical degree from the Universidade Nova de Lisboa, Portugal in 2004. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at MedStar Washington Hospital Center/MedStar Georgetown University Hospital in Washington, DC. She was faculty at MedStar Georgetown University Hospital from 2015 to 2020 where she served as the institutional PI for Alliance and the co-PI for the National Capital Area (NCA) Minority/Underserved NCORP. In 2020, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on inflammatory breast cancer, triple-negative breast cancer, BRCA-associated breast cancers and novel therapies in the treatment of breast cancer. Dr. Lynce is rated as an Elite provider by MediFind in the treatment of Inflammatory Breast Cancer. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy. Dr. Lynce is board certified in Medical Oncology.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Inflammatory Breast Cancer
Elite in Inflammatory Breast Cancer
Referral may be required

Dana-Farber Cancer Institute, Breast Oncology Program

450 Brookline Avenue, Susan F. Smith Center For Women's Cancers, 
Boston, MA 
Languages Spoken:
English

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Inflammatory Breast Cancer. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology.

What are the latest Inflammatory Breast Cancer Clinical Trials?
Prophylactic Lymphovenous Bypass Procedure Following Axillary Lymphadenectomy: A Prospective Observational Study

Summary: This pilot trial studies whether a procedure called lymphovenous bypass would prevent lymphedema (arm swelling) in patients with inflammatory breast cancer or non-inflammatory breast cancer that has spread to nearby tissues or lymph nodes or melanoma. The lymphovenous bypass procedure creates a path for lymphatic fluid to flow away from the arms. It is usually done after a diagnosis of lymphedema....

Match to trials
Find the right clinical trials for you in under a minute
Get started
Multi-center MRD Registry for Inflammatory Breast Cancer

Summary: To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.

Who are the sources who wrote this article ?

Published Date: May 13, 2022
Published By: Genetic and Rare Diseases Informnation Center